Keywords
How to Cite
Abstract
Introduction. Incidence, mortality and survival studies are important indicators of success in the fight against cancer. The incidence, mortality and survival rates for women with gynecological cancers vary widely between regions of the world, depending on geographical location, economic status and level of health care.
Aim. Comparative analysis of the dynamics of incidence, mortality, and survival of patients with cervical cancer in the Northwestern Federal District of the Russian Federation (NWFD RF), in the Russian Federation as a whole, and in the northern European countries located at the same latitude over a 10-year period (2010-2020).
Materials and Methods. Incidence, mortality and survival data for the period 2010 to 2020 according to the newly created Population Cancer Registry Database (DB PRR) of the NWFD RF, which includes 11 constituent entities of the Russian Federation. Incidence, mortality and survival rates were compared with those in the Nordic countries; data were obtained from the Association of the Nordic Cancer Registries website https://nordcan.iarc.fr/en.
Results. The incidence rate of cervical cancer in Russia as a whole and in Northern Europe remains stable, and there is a slight decrease in the NWFD from 2010 to 2020. However, the incidence rate in Russia and the NWFD is relatively higher than in Northern Europe. The regions of Arkhangelsk, Kaliningrad, Novgorod and Pskov had the highest incidence rates of cervical cancer in the NWFD. The highest incidence rates of cervical cancer in the Nordic countries were recorded in the Faroe Islands, Greenland and Norway, and the lowest in Finland. Cervical cancer mortality is decreasing in Russia, the NWFD and northern European countries, but there is still a gap between European and Russian indicators. At the same time, there is a trend towards an increase in the relative survival of cervical cancer patients in Northern European countries between 2017 and 2021, while survival rates in the NWFD regions do not show an upward trend.
Conclusion. It is necessary to increase the efficiency of diagnosis and treatment of cervical cancer in the regions of the NWFD RF.
References
Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.-DOI: https://doi.org/10.3322/caac.21660.
Cancer Incidence in Five Continents. Volume XII. Registry Summary tables. URL: https://gco.iarc.fr/media/ci5/data/vol12/Indices/C53.pdf/vol12/Indices/C53.pdf.
Singh D., Vignat J., Lorenzoni V., et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023; 11(2):e197-e206.-DOI: https://doi.org/10.1016/S2214-109X(22)00501-0.
Riano I., Contreras-Chavez P., Pabon C.M., et al. An overview of cervical cancer prevention and control in Latin America and the Caribbean Countries. Hematol Oncol Clin North Am. 2024; 38(1): 13-33.-DOI: https://doi.org/10.1016/j.hoc.2023.05.012.
Simms K.T., Steinberg J., Caruana M., et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019; 20(3): 394-407.-DOI: https://doi.org/10.1016/S1470-2045(18)30836-2.
Utada M., Chernyavskiy P., Lee W.J., et al. Increasing risk of uterine cervical cancer among young Japanese women: Comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer. 2019; 144(9): 2144-2152.-DOI: https://doi.org/10.1002/ijc.32014.
Castanon A., Sasieni P. Is the recent increase in cervical cancer in women aged 20-24years in England a cause for concern? Prev Med. 2018; 107: 21-28.-DOI: https://doi.org/10.1016/j.ypmed.2017.12.002.
McDonald S.A., Qendri V., Berkhof J., et al. Disease burden of human papillomavirus infection in the Netherlands, 1989-2014: the gap between females and males is diminishing. Cancer Causes Control. 2017; 28(3): 203-214.-DOI: https://doi.org/10.1007/s10552-017-0870-6.
Pilleron S., Cabasag C.J., Ferlay J., et al. Cervical cancer burden in Latin America and the Caribbean: Where are we? Int J Cancer. 2020; 147(6): 1638-1648.-DOI: https://doi.org/10.1002/ijc.32956.
Bray F., Lortet-Tieulent J., Znaor A., et al. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia. Vaccine. 2013; 31 Suppl 7: H32-45.-DOI: https://doi.org/10.1016/j.vaccine.2013.02.071.
Ellis L., Woods L.M., Estève J., et al. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014; 135(8): 1774-82.-DOI: https://doi.org/10.1002/ijc.28990.
Tichanek F., Försti A., Hemminki O., et al. Incidence, and mortality trends in female cancers in the nordic countries. Obstet Gynecol Int. 2023; 2023: 6909414.-DOI: https://doi.org/10.1155/2023/6909414.
Comparable cancer statistics for Denmark, Finland, Iceland, Norway, Sweden, the Faroe Islands, and Greenland. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en.
Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П. А. Герцена. 2012; 260. [Malignant neoplasms in Russia in 2010 (morbidity and mortality). Ed by Chissov V.I., Starinsky V.V., Petrova G.V. Moscow: P. Hertsen MORI – branch of the FSBI NMRRC of the Ministry of Health of Russia. 2012: 260. (In Rus)].
Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2017: 250. [Malignant neoplasms in Russia in 2015 (morbidity and mortality). Ed by Kaprin A.D., Starinsky V.V., Petrova G.V. Moscow: P. Hertsen MORI – branch of the FSBI NMRRC of the Ministry of Health of Russia. 2017: 250 (In Rus)].
Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2019: 250. [Malignant neoplasms in Russia in 2018 (morbidity and mortality). Ed by Kaprin A.D., Starinsky V.V., Petrova G.V. Moscow: P. Hertsen MORI – branch of the FSBI NMRRC of the Ministry of Health of Russia. 2019: 250 (In Rus)].
Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2020: 214. [Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed by Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Moscow: P. Hertsen MORI – branch of the FSBI NMRRC of the Ministry of Health of Russia. 2020: 214 (In Rus)].
Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2021: 252. [Malignant neoplasms in Russia in 2020 (morbidity and mortality). Kaprin A.D., Starinsky V.V, Shakhzadova A.O. Moscow: P. Hertsen MORI – branch of the FSBI NMRRC of the Ministry of Health of Russia. 2021: 252. (In Rus)].
Выживаемость онкологических больных. Под ред. В.М. Мерабишвили, И.В. Кисельникова, О.Ф. Чепик и др. Выпуск 2, Часть I. Санкт-Петербург: Издательско-полиграфическая компания «КОСТА». 2011: 332.-ISBN 978-5-91258-176-2. [Survival of cancer patients. Ed by V.M. Merabishvili, I.V. Kiselnikova, O.F. Chepik, et al. Issue 2, Part I. St. Petersburg: Publishing and printing company «COSTA». 2011; 332.-ISBN: 978-5-91258-176-2. (In Rus)].
Мерабишвили В.М. Выживаемость онкологических больных. Выпуск второй. Часть II. Под ред. Ю.А. Щербука. СПб.: ООО «Издательско-полиграфическая компания «КОСТА». 2011: 408. [Merabishvili V.M. Survival of cancer patients. Issue two. Part II. Ed by Yu.A. Shcherbuk. St. Petersburg: «COSTA». 2011: 408. (In Rus)].
Мерабишвили В.М. Онкологическая статистика (традиционные методы, новые информационные технологии): руководство для врачей. Часть I. СПб.: ООО «Издательско-полиграфическая компания «КОСТА». 2011: 221. [Merabishvili V.M. Oncology statistics (traditional methods, new information technologies): a guide for doctors. Part I. St. Petersburg: «COSTA». 2011: 221. (In Rus)].
Мерабишвили В.М. Онкологическая статистика (традиционные методы, новые информационные технологии): руководство для врачей. Часть II. - СПб.: ООО "Издательско-полиграфическая компания «КОСТА». 2011: 248. [Merabishvili V.M. Oncology statistics (traditional methods, new information technologies): a guide for doctors. Part II. St. Petersburg: «COSTA». 2011: 248 (In Rus)].
Мерабишвили В.М. Злокачественные новообразования в Северо-Западном федеральном округе России (заболеваемость, смертность, достоверность учета, выживаемость больных). Экспресс-информация. Выпуск пятый. Под ред. проф. А.М. Беляева, проф. А.М. Щербакова. СПб.: Т8 Издательские технологии. 2020: 236. [Merabishvili V.M. Malignant tumors in the North-West Federal Region of Russia (morbidity, mortality, index accuracy, survival). Express-information. Fifth Issue. Editors: Prof. A.M. Belyaev, Prof. A.M. Shcherbakov. St.Petersburg: T8 Publishing technologies. 2020: 236. (In Rus)].
Мерабишвили В.М. Злокачественные новообразования в Северо-Западном федеральном округе России (заболеваемость, смертность, достоверность учета, выживаемость больных). Экспресс-информация. Выпуск шестой. Пособие для врачей. Под ред. чл.-корр. РАН, проф. А.М. Беляева. СПб. 2023: 498. [Merabishvili V.M. Malignant tumors in the North-West Federal Region of Russia (Morbidity, mortality, prevalence rate, survival). Express-information. Sixth Issue. Manual for doctors. Ed. by A.M. Belyaev. SPb: T8 Publishing technologies. 2020: 498. (In Rus)].
Incidence, Females, [2010-2020]. NORDCAN countries. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=0.
Incidence, Females, [2010-2020]. Denmark. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=208.
Incidence, Females, [2010-2020]. Faroe Islands. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=234.
Incidence, Females, [2010-2020]. Finland. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=246.
Incidence, Females, [2010-2020]. Greenland. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=304.
Incidence, Females, [2010-2020]. Iceland. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=352.
Incidence, Females, [2010-2020]. Norway. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=578.
Incidence, Females, [2010-2020]. Sweden. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?sexes=2&types=0&cancers=190&years=2010_2020&group_years=1&group_cancers=0&multiple_cancers=0&age_end=17&mode=year&group_populations=1&populations=752.
Age-Standardized Rate (Nordic) per 100 000 , Incidence, Females. Cervix uteri. NORDCAN countries. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/trends?populations=0&sexes=2&cancers=190&years=2010_2020.
Mortality, Females, [2010-2021]. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/tables?years=2010_2021&types=1&sexes=2&cancers=190&populations=0.
Age-Standardized Rate (Nordic) per 100 000, Mortality, Females. All sites. NORDCAN countries. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/trends?types=1&sexes=2&populations=0&years=2010_2020.
Age-specific 5-year relative survival (%), Females. Cervix uteri. Denmark. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/survival_age_specific?sexes=2&cancers=190&populations=208.
Age-standardized relative survival (%) [95% CI], Females. Cervix uteri. Association of the Nordic Cancer Registries. Nordcan 2.0 – IARC. URL: https://nordcan.iarc.fr/en/dataviz/survival_table?mode=cancer&sexes=2&cancers=190&survival=1&reset=1.
Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189(1): 12-9.-DOI: https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
Serrano B., Brotons M., Bosch F.X., Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018; 47: 14-26.-DOI: https://doi.org/10.1016/j.bpobgyn.2017.08.006.
Sung H., Ferlay J., Siegel R.L., et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.-DOI: https://doi.org/10.3322/caac.21660.
Tichanek F., Försti A., Hemminki O., et al. Survival, incidence, and mortality trends in female cancers in the Nordic countries. Obstet Gynecol Int. 2023; 6909414.-DOI: https://doi.org/10.1155/2023/6909414.
Landy R., Pesola F., Castañón A., Sasieni P. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer. 2016; 115(9): 1140-1146.-DOI: https://doi.org/10.1038/bjc.2016.290.
Landoni F., Maneo A., Colombo A., et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997; 350(9077): 535-40.-DOI: https://doi.org/10.1016/S0140-6736(97)02250-2.
George E.M., Tergas A.I., Ananth C.V., et al. Safety and tolerance of radical hysterectomy for cervical cancer in the elderly. Gynecol Oncol. 2014; 134(1): 36-41.-DOI: https://doi.org/10.1016/j.ygyno.2014.04.010.
NCI Issues Clinical Announcement on Cervical Cancer. Chemotherapy Plus Radiation Improves Survival. (12.10.2014). URL: http://www.nih.gov/news/pr/feb99/nci-22.htm.
Wright J.D., Chen L., Tergas A.I., et al. Population-level trends in relative survival for cervical cancer. Am J Obstet Gynecol. 2015; 213(5): 670.e1-7.-DOI: https://doi.org/10.1016/j.ajog.2015.07.012.
Hemminki K., Försti A., Liska V., et al. Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements. Int J Cancer. 2023; 152(9): 1837-1846.-DOI: https://doi.org/10.1002/ijc.34416.
Walsh R.J., Tan D.S.P. The role of immunotherapy in the treatment of advanced cervical cancer: current status and future perspectives. J Clin Med. 2021; 10(19): 4523.-DOI: https://doi.org/10.3390/jcm10194523.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024